Merck从LaNova药品公司获得30亿美元的新癌症治疗执照。 Merck acquires a $3 billion license for a new cancer treatment from LaNova Medicines.

Merck & Co. 获得了开发LM-299的独家全球许可证,LM-299是拉诺瓦制药公司的一项新型癌症治疗方案,价值超过30亿美元。 Merck & Co. has acquired an exclusive global license to develop LM-299, a novel cancer treatment from LaNova Medicines, in a deal valued at over $3 billion. 该协议包括一笔5.88亿美元的预付付款和27亿美元的可能的里程碑付款。 The agreement includes a $588 million upfront payment and potential milestone payments of $2.7 billion. Merck将在中国对LM-299进行第一阶段的研究,目的是扩大其肿瘤管道,并推广药物,为患者提供治疗。 Merck will conduct a Phase 1 study of LM-299 in China, aiming to expand its oncology pipeline and advance the drug for patient benefit.